Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in 2025.

External hiring of finance chiefs hit a 10-year high in 2024, according to Crist Kolder Associates' annual report.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of ...

New York, New York-- (Newsfile Corp. - January 22, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute ...

Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

The city of Greensboro has joined a national litigation campaign suing the nation's three largest pharmacy benefit managers and three largest insulin manufacturers with the goal of lowering insulin pr ...

Abbott also is a buy for its dividend strength. As a Dividend King it's raised its dividend for more than 50 consecutive ...

There are many ways to diversify beyond the S&P 500. One is to hold shares of the Invesco S&P 500 Equal Weight ETF RSP. Another, according to Davis, is to take an even broader index-fund approach. One ...

In keeping with the long-term outlook of the strategy, Constantino and Skorski assess the durability of each company’s advantages ... Broadcom, Eli Lily, and Meta Platforms—accounted for ...

The sophomore was the 2024 ISL Men’s varsity champion, an ISL All-League selection, and the ISL’s most valuable performer.